Regency Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Regency Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-58,000	Closed	-$578K	–	62
2025 Q2	$578K	Buy	+58,000	New	+$467K	0.3%	45

Other funds holding ITOS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Regency Capital Management's ITOS Position: Q3 2025 in Review

Regency Capital Management sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 58,000 shares — an estimated $578K sold.

Regency Capital Management first reported a position in ITOS in Q2 2025 and held it in 1 quarter. The position peaked at $578K in Q2 2025. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

Regency Capital Management reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
Regency Capital Management sold 58,000 iTeos Therapeutics shares in Q3 2025, an estimated $578K.
Regency Capital Management first reported a position in iTeos Therapeutics in Q2 2025 and held it in 1 quarter.
Regency Capital Management's iTeos Therapeutics position peaked at $578K in Q2 2025.
1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Regency Capital Management's 13F filing for Q3 2025, filed 21 Oct 2025.